Rodman & Renshaw Analyst Recommendations & Stock Picks

Name: Community Performance Rating
Item: Rodman & Renshaw
Rating: 2.6
Author: MarketBeat

View the latest stock recommendations issued by analysts at Rodman & Renshaw. This page tracks publicly reported analyst upgrades and downgrades, buy/hold/sell ratings, and price target changes for publicly traded companies. All data is compiled from credible public sources and updated regularly to reflect new insights from Rodman & Renshaw's equity research team. MarketBeat is not affiliated with or endorsed by Rodman & Renshaw.

2 Analysts
Updated 5/28/2026

Brokerage Ranking: Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Total Ratings: 23 Last 12 Months
Buy Ratings: 23 Last 12 Months
Sell Ratings: 0 Last 12 Months
Companies Covered: 19 Last 12 Months

Company	Current Price	Report Date	Analyst	Action	Price Target	Rating	Details
BOLT Bolt Biotherapeutics	$5.26 -0.8%	5/28/2026	Michael G. King Jr. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$22.00	Buy	View details for Rodman & Renshaw rating of Bolt Biotherapeutics (NASDAQ:BOLT) on 5/28/2026
SABS SAB Biotherapeutics	$3.62 +1.3%	5/11/2026	Seema Sheoran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	$13.00	Buy	View details for Rodman & Renshaw rating of SAB Biotherapeutics (NASDAQ:SABS) on 5/11/2026
SANA Sana Biotechnology	$3.19 +1.8%	5/11/2026		Initiated Coverage	$16.00	Buy	View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 5/11/2026
ABNB Airbnb	$134.36 -0.1%	5/4/2026		Initiated Coverage		Buy	View details for Rodman & Renshaw rating of Airbnb (NASDAQ:ABNB) on 5/4/2026
AVXL Anavex Life Sciences	$3.01 +2.2%	5/4/2026		Initiated Coverage	$20.00	Buy	View details for Rodman & Renshaw rating of Anavex Life Sciences (NASDAQ:AVXL) on 5/4/2026
HURA TuHURA Biosciences	$2.25 -4.5%	4/15/2026		Initiated Coverage		Buy	View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 4/15/2026
CAMP CAMP4 Therapeutics	$4.39 -2.3%	4/14/2026	Seema Sheoran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$7.00	Buy	View details for Rodman & Renshaw rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 4/14/2026
CAMP CAMP4 Therapeutics	$4.39 -2.3%	4/14/2026	Seema Sheoran Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$7.00	Buy	View details for Rodman & Renshaw rating of CAMP4 Therapeutics (NASDAQ:CAMP) on 4/14/2026
SABS SAB Biotherapeutics	$3.62 +1.3%	4/2/2026		Initiated Coverage	$13.00	Buy	View details for Rodman & Renshaw rating of SAB Biotherapeutics (NASDAQ:SABS) on 4/2/2026
ENTA Enanta Pharmaceuticals	$13.16 -0.5%	3/26/2026		Initiated Coverage	$20.00	Buy	View details for Rodman & Renshaw rating of Enanta Pharmaceuticals (NASDAQ:ENTA) on 3/26/2026
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
SGMT Sagimet Biosciences	$7.21 -0.8%	3/26/2026		Initiated Coverage	$28.00	Buy	View details for Rodman & Renshaw rating of Sagimet Biosciences (NASDAQ:SGMT) on 3/26/2026
BTAI BioXcel Therapeutics	$1.21 -4.4%	3/17/2026	Michael King Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$17.00	Buy	View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/17/2026
ELTX Elicio Therapeutics	$11.28 +6.3%	3/10/2026	Michael King Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Elicio Therapeutics (NASDAQ:ELTX) on 3/10/2026
KPTI Karyopharm Therapeutics	$9.15 +0.5%	3/10/2026	Michael King Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 3/10/2026
ELTX Elicio Therapeutics	$11.28 +6.3%	3/9/2026	Michael King Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$17.00	Buy	View details for Rodman & Renshaw rating of Elicio Therapeutics (NASDAQ:ELTX) on 3/9/2026
KPTI Karyopharm Therapeutics	$9.15 +0.5%	3/9/2026	Michael King Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$28.00	Buy	View details for Rodman & Renshaw rating of Karyopharm Therapeutics (NASDAQ:KPTI) on 3/9/2026
MIRA MIRA Pharmaceuticals	$1.08 -0.5%	1/13/2026		Initiated Coverage		Buy	View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 1/13/2026
TELO Telomir Pharmaceuticals	$1.30 +1.6%	1/13/2026		Initiated Coverage		Buy	View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 1/13/2026
AAPG Ascentage Pharma Group International	$19.72 -0.8%	1/13/2026		Initiated Coverage	$48.00	Buy	View details for Rodman & Renshaw rating of Ascentage Pharma Group International (NASDAQ:AAPG) on 1/13/2026
BMEA Biomea Fusion	$1.39 +0.4%	1/13/2026		Initiated Coverage	$8.00	Buy	View details for Rodman & Renshaw rating of Biomea Fusion (NASDAQ:BMEA) on 1/13/2026
JSPR Jasper Therapeutics	$0.86 -3.4%	1/13/2026		Initiated Coverage	$17.00	Buy	View details for Rodman & Renshaw rating of Jasper Therapeutics (NASDAQ:JSPR) on 1/13/2026
BTAI BioXcel Therapeutics	$1.21 -4.4%	3/19/2025	Elemer Piros Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	$65.00	Buy	View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/19/2025
BTAI BioXcel Therapeutics	$1.21 -4.4%	3/19/2025	E. Piros Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of BioXcel Therapeutics (NASDAQ:BTAI) on 3/19/2025
TELO Telomir Pharmaceuticals	$1.30 +1.6%	2/21/2025		Initiated Coverage	$15.00	Buy	View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/21/2025
TELO Telomir Pharmaceuticals	$1.30 +1.6%	2/20/2025	E. Piros Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Telomir Pharmaceuticals (NASDAQ:TELO) on 2/20/2025
CRDL Cardiol Therapeutics	$1.26 -2.0%	1/28/2025		Initiated Coverage	$7.00	Buy	View details for Rodman & Renshaw rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025
CRDL Cardiol Therapeutics	$1.26 -2.0%	1/28/2025	B. Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Cardiol Therapeutics (NASDAQ:CRDL) on 1/28/2025
INDV Indivior	$36.11 -1.4%	1/28/2025	B. Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Indivior (NASDAQ:INDV) on 1/28/2025
INDV Indivior	$36.11 -1.4%	1/28/2025		Initiated Coverage	$16.00	Buy	View details for Rodman & Renshaw rating of Indivior (NASDAQ:INDV) on 1/28/2025
INMB INmune Bio	$1.42 -0.4%	1/28/2025		Initiated Coverage	$23.00	Buy	View details for Rodman & Renshaw rating of INmune Bio (NASDAQ:INMB) on 1/28/2025
INMB INmune Bio	$1.42 -0.4%	1/28/2025	E. Piros Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of INmune Bio (NASDAQ:INMB) on 1/28/2025
PYPD PolyPid	$4.72 -0.9%	1/28/2025	B. Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of PolyPid (NASDAQ:PYPD) on 1/28/2025
PYPD PolyPid	$4.72 -0.9%	1/28/2025		Initiated Coverage	$13.00	Buy	View details for Rodman & Renshaw rating of PolyPid (NASDAQ:PYPD) on 1/28/2025
TLPH Talphera	$0.80 -2.9%	1/28/2025		Initiated Coverage	$4.00	Buy	View details for Rodman & Renshaw rating of Talphera (NASDAQ:TLPH) on 1/28/2025
TLPH Talphera	$0.80 -2.9%	1/28/2025	B. Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Talphera (NASDAQ:TLPH) on 1/28/2025
ATRA Atara Biotherapeutics	$10.49 -6.8%	1/21/2025	T. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade		Strong-Buy ➝ Hold	View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 1/21/2025
ATRA Atara Biotherapeutics	$10.49 -6.8%	12/20/2024		Initiated Coverage	$25.00	Buy	View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024
ATRA Atara Biotherapeutics	$10.49 -6.8%	12/20/2024	T. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Atara Biotherapeutics (NASDAQ:ATRA) on 12/20/2024
HURA TuHURA Biosciences	$2.25 -4.5%	12/19/2024		Initiated Coverage	$11.00	Buy	View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024
HURA TuHURA Biosciences	$2.25 -4.5%	12/19/2024	T. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of TuHURA Biosciences (NASDAQ:HURA) on 12/19/2024
SpaceX eyes a 1.75 trillion valuation - here's what to know (Ad) Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500. See how to get positioned in SpaceX before the announcement goes public
THAR Tharimmune	$3.11 -3.7%	12/6/2024		Initiated Coverage	$17.00	Buy	View details for Rodman & Renshaw rating of Tharimmune (NASDAQ:THAR) on 12/6/2024
THAR Tharimmune	$3.11 -3.7%	12/6/2024	E. Piros Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Tharimmune (NASDAQ:THAR) on 12/6/2024
ACHV Achieve Life Sciences	$5.44 +2.5%	11/14/2024		Initiated Coverage	$12.00	Buy	View details for Rodman & Renshaw rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024
ACHV Achieve Life Sciences	$5.44 +2.5%	11/14/2024	B. Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Achieve Life Sciences (NASDAQ:ACHV) on 11/14/2024
EPRX Eupraxia Pharmaceuticals	$7.22 -2.2%	11/14/2024		Initiated Coverage	$9.00	Buy	View details for Rodman & Renshaw rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024
EPRX Eupraxia Pharmaceuticals	$7.22 -2.2%	11/14/2024	B. Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 11/14/2024
OMER Omeros	$10.97 -1.7%	11/14/2024	B. Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 11/14/2024
OMER Omeros	$10.97 -1.7%	11/14/2024		Initiated Coverage	$9.00	Buy	View details for Rodman & Renshaw rating of Omeros (NASDAQ:OMER) on 11/14/2024
RMTI Rockwell Medical	$0.74 -2.1%	11/14/2024		Initiated Coverage	$5.00	Buy	View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024
RMTI Rockwell Medical	$0.74 -2.1%	11/14/2024	B. Folkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Rockwell Medical (NASDAQ:RMTI) on 11/14/2024
BCAX Bicara Therapeutics	$21.88 +0.6%	11/5/2024		Initiated Coverage	$48.00	Buy	View details for Rodman & Renshaw rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024
BCAX Bicara Therapeutics	$21.88 +0.6%	11/5/2024	T. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Bicara Therapeutics (NASDAQ:BCAX) on 11/5/2024
QNCX Quince Therapeutics	$1.21 +3.0%	10/29/2024		Initiated Coverage	$110.00	Buy	View details for Rodman & Renshaw rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024
QNCX Quince Therapeutics	$1.21 +3.0%	10/29/2024	E. Piros Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Quince Therapeutics (NASDAQ:QNCX) on 10/29/2024
ANRO Alto Neuroscience	$20.46 +1.2%	10/23/2024		Downgrade		Buy ➝ Neutral	View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 10/23/2024
MNPR Monopar Therapeutics	$66.25 +2.8%	10/11/2024		Initiated Coverage	$50.00	Buy	View details for Rodman & Renshaw rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/11/2024
KYTX Kyverna Therapeutics	$8.66 +0.1%	10/9/2024		Initiated Coverage	$16.00	Buy	View details for Rodman & Renshaw rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024
KYTX Kyverna Therapeutics	$8.66 +0.1%	10/9/2024	T. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Kyverna Therapeutics (NASDAQ:KYTX) on 10/9/2024
NKTX Nkarta	$3.25 -1.7%	10/9/2024	T. Butler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of Nkarta (NASDAQ:NKTX) on 10/9/2024
NKTX Nkarta	$3.25 -1.7%	10/9/2024		Initiated Coverage	$14.00	Buy	View details for Rodman & Renshaw rating of Nkarta (NASDAQ:NKTX) on 10/9/2024
MIRA MIRA Pharmaceuticals	$1.08 -0.5%	9/30/2024		Initiated Coverage	$17.00	Buy	View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024
MIRA MIRA Pharmaceuticals	$1.08 -0.5%	9/30/2024	E. Piros Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade		Strong-Buy	View details for Rodman & Renshaw rating of MIRA Pharmaceuticals (NASDAQ:MIRA) on 9/30/2024
BMEA Biomea Fusion	$1.39 +0.4%	9/26/2024		Upgrade	$18.00	Neutral ➝ Buy	View details for Rodman & Renshaw rating of Biomea Fusion (NASDAQ:BMEA) on 9/26/2024
EBS Emergent Biosolutions	$9.34 +1.7%	9/13/2024		Reiterated Rating	$16.00 ➝ $16.00	Buy	View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 9/13/2024
ATHA Athira Pharma	$9.64 -1.7%	9/4/2024		Downgrade		Buy ➝ Neutral	View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 9/4/2024
PASG Passage Bio	$5.82 +1.9%	9/3/2024		Initiated Coverage	$140.00	Buy	View details for Rodman & Renshaw rating of Passage Bio (NASDAQ:PASG) on 9/3/2024
CRMD CorMedix	$8.43 +0.1%	8/26/2024		Initiated Coverage	$13.00	Buy	View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/26/2024
DERM Journey Medical	$6.37 +2.7%	8/22/2024		Initiated Coverage	$9.00	Buy	View details for Rodman & Renshaw rating of Journey Medical (NASDAQ:DERM) on 8/22/2024
EBS Emergent Biosolutions	$9.34 +1.7%	8/22/2024		Initiated Coverage	$16.00	Buy	View details for Rodman & Renshaw rating of Emergent Biosolutions (NYSE:EBS) on 8/22/2024
MIST Milestone Pharmaceuticals	$1.44	8/22/2024		Initiated Coverage	$9.00	Buy	View details for Rodman & Renshaw rating of Milestone Pharmaceuticals (NASDAQ:MIST) on 8/22/2024
ATHA Athira Pharma	$9.64 -1.7%	8/19/2024		Initiated Coverage	$220.00	Buy	View details for Rodman & Renshaw rating of Athira Pharma (NASDAQ:ATHA) on 8/19/2024
FLNA Cassava Sciences	$1.53 -1.3%	8/8/2024		Reiterated Rating	$107.00 ➝ $107.00	Buy	View details for Rodman & Renshaw rating of Cassava Sciences (NASDAQ:FLNA) on 8/8/2024
IPSC Century Therapeutics	$2.37 -0.6%	8/8/2024		Initiated Coverage	$6.00	Buy	View details for Rodman & Renshaw rating of Century Therapeutics (NASDAQ:IPSC) on 8/8/2024
CRSP CRISPR Therapeutics	$55.73 -1.2%	8/2/2024		Initiated Coverage	$90.00	Buy	View details for Rodman & Renshaw rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/2/2024
ANVS Annovis Bio	$1.96 +2.9%	7/2/2024		Reiterated Rating	$67.00 ➝ $67.00	Buy	View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 7/2/2024
CGTX Cognition Therapeutics	$1.20 +0.4%	7/2/2024		Reiterated Rating	$14.00 ➝ $14.00	Buy	View details for Rodman & Renshaw rating of Cognition Therapeutics (NASDAQ:CGTX) on 7/2/2024
CYPH Cypherpunk Technologies	$1.16 +3.1%	6/28/2024		Initiated Coverage	$8.00	Buy	View details for Rodman & Renshaw rating of Cypherpunk Technologies (NASDAQ:CYPH) on 6/28/2024
NKTR Nektar Therapeutics	$64.85 -0.3%	6/28/2024		Initiated Coverage	$30.00	Buy	View details for Rodman & Renshaw rating of Nektar Therapeutics (NASDAQ:NKTR) on 6/28/2024
SANA Sana Biotechnology	$3.19 +1.8%	6/26/2024		Initiated Coverage	$16.00	Buy	View details for Rodman & Renshaw rating of Sana Biotechnology (NASDAQ:SANA) on 6/26/2024
ANRO Alto Neuroscience	$20.46 +1.2%	6/21/2024		Initiated Coverage	$43.00	Buy	View details for Rodman & Renshaw rating of Alto Neuroscience (NYSE:ANRO) on 6/21/2024
COYA Coya Therapeutics	$4.79 -0.8%	6/13/2024		Initiated Coverage	$18.00	Buy	View details for Rodman & Renshaw rating of Coya Therapeutics (NASDAQ:COYA) on 6/13/2024
HRTX Heron Therapeutics	$0.87 -2.7%	6/13/2024		Initiated Coverage	$7.00	Buy	View details for Rodman & Renshaw rating of Heron Therapeutics (NASDAQ:HRTX) on 6/13/2024
MNKD MannKind	$3.85 +5.6%	6/13/2024		Initiated Coverage	$8.00	Buy	View details for Rodman & Renshaw rating of MannKind (NASDAQ:MNKD) on 6/13/2024
RANI Rani Therapeutics	$0.97 +1.5%	6/13/2024		Initiated Coverage	$10.00	Buy	View details for Rodman & Renshaw rating of Rani Therapeutics (NASDAQ:RANI) on 6/13/2024
SCLX Scilex	$9.39 +30.2%	6/13/2024		Initiated Coverage	$455.00	Buy	View details for Rodman & Renshaw rating of Scilex (NASDAQ:SCLX) on 6/13/2024
TRVI Trevi Therapeutics	$14.34 -0.8%	6/13/2024		Initiated Coverage	$7.00	Buy	View details for Rodman & Renshaw rating of Trevi Therapeutics (NASDAQ:TRVI) on 6/13/2024
ANVS Annovis Bio	$1.96 +2.9%	6/4/2024		Initiated Coverage	$67.00	Buy	View details for Rodman & Renshaw rating of Annovis Bio (NYSE:ANVS) on 6/4/2024
BHC Bausch Health Cos	$5.32 -1.8%	8/10/2017		Reiterated Rating	$17.00	Neutral	View details for Rodman & Renshaw rating of Bausch Health Cos (NYSE:BHC) on 8/10/2017
CRMD CorMedix	$8.43 +0.1%	8/10/2017		Lower Price Target	$25.00 ➝ $15.00	Buy	View details for Rodman & Renshaw rating of CorMedix (NASDAQ:CRMD) on 8/10/2017
GEVO Gevo	$1.89 -0.8%	8/9/2017		Reiterated Rating	$240.00	Buy	View details for Rodman & Renshaw rating of Gevo (NASDAQ:GEVO) on 8/9/2017
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad) We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. 👉 Unlock the ticker now and get it completely free.
POETF POET Technologies	$13.26 -0.2%	8/7/2017		Initiated Coverage		Buy	View details for Rodman & Renshaw rating of POET Technologies (OTCMKTS:POETF) on 8/7/2017
VERU Veru	$2.33 +0.4%	7/26/2017		Initiated Coverage	$50.00	Buy	View details for Rodman & Renshaw rating of Veru (NASDAQ:VERU) on 7/26/2017
PLUG Plug Power	$3.99 -3.3%	7/24/2017		Reiterated Rating	$4.00	Buy	View details for Rodman & Renshaw rating of Plug Power (NASDAQ:PLUG) on 7/24/2017
CAPR Capricor Therapeutics	$30.06 +3.3%	7/22/2017		Reiterated Rating	$2.15	Buy	View details for Rodman & Renshaw rating of Capricor Therapeutics (NASDAQ:CAPR) on 7/22/2017
BYSI BeyondSpring	$1.70 -1.2%	7/14/2017		Boost Price Target	$43.00 ➝ $50.00	Buy	View details for Rodman & Renshaw rating of BeyondSpring (NASDAQ:BYSI) on 7/14/2017
FBIO Fortress Biotech	$2.82 +0.2%	7/11/2017		Initiated Coverage	$165.00	Buy	View details for Rodman & Renshaw rating of Fortress Biotech (NASDAQ:FBIO) on 7/11/2017
AQMS Aqua Metals	$4.10 +0.6%	7/2/2017		Initiated Coverage	$5,000.00 ➝ $5,000.00	Buy	View details for Rodman & Renshaw rating of Aqua Metals (NASDAQ:AQMS) on 7/2/2017
EMAN eMagin	$2.07	6/23/2017		Reiterated Rating	$4.00	Buy	View details for Rodman & Renshaw rating of eMagin (NYSEAMERICAN:EMAN) on 6/23/2017
AQMS Aqua Metals	$4.10 +0.6%	6/22/2017		Initiated Coverage	$5,000.00	Buy	View details for Rodman & Renshaw rating of Aqua Metals (NASDAQ:AQMS) on 6/22/2017
USA Americas Silver	C$8.48 +1.2%	6/15/2017		Initiated Coverage	C$4.00	Buy	View details for Rodman & Renshaw rating of Americas Silver (TSE:USA) on 6/15/2017

MarketBeat Community Rating for Rodman & Renshaw

MarketBeat's community ratings are surveys of what our community members think about Rodman & Renshaw and other research firms in the last 90 days. Vote "Outperform" if you believe Rodman & Renshaw's recommendations will outperform the broader market over the long term. Vote "Underperform" if you believe Rodman & Renshaw's recommendations will underperform the broader market over the long term. You may vote once every thirty days.

Log in to vote on this brokerage.

COMMUNITY RATINGS: 2.6out of 5 (last 90 days)
2.6 of 5 stars
OUTPERFORM VOTES: 27 Believe will outperform the market
UNDERPERFORM VOTES: 25 Believe will underperform the market

Analysts at Rodman & Renshaw

Rodman & Renshaw's equity research team has issued ratings on 19 companies across 2 sectors over the past 12 months, covered by 2 analysts. The Rodman & Renshaw analysts below are listed by number of ratings issued in the last year.

Rodman & Renshaw Stock Coverage by Sector

Rodman & Renshaw concentrates its research most heavily in Medical (94.7%) and Consumer Discretionary (5.3%). The chart below shows how Rodman & Renshaw's 19 rated companies are distributed across all 2 sectors it covers.

Medical
18 companies
94.7%
Consumer Discretionary
1 company
5.3%

Best & Worst Calls

Best Call
0000.0%
NASDAQ:AGEN
Reiterated Rating • Sep 26, 2011
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
OTCMKTS:PUDA
Lower Price Target • Mar 15, 2011
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Similarly Rated Firms

Rodman & Renshaw - Frequently Asked Questions

Rodman & Renshaw's analysts currently have buy-equivalent ratings on 19 companies. Recent upgrades to buy include Karyopharm Therapeutics and Elicio Therapeutics.

Rodman & Renshaw has the deepest coverage in Medical (94.7% of rated companies) and Consumer Discretionary (5.3% of rated companies).

Rodman & Renshaw issued 23 ratings over the last 12 months across 19 companies â€” an average of roughly 2 rating actions per month. These include initiated coverage, reiterated rating and upgrade. MarketBeat tracks every rating change as it's published so you can see the most current Rodman & Renshaw analyst actions.

A buy rating indicates the analyst expects the stock to outperform the market over the next 12 months. A hold suggests the stock will perform in line with the market. A sell rating indicates expected underperformance. Rodman & Renshaw uses Outperform, Market Perform, and Underperform as their equivalents.

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?